TC-1 Syngeneic Model Service for Cervical Cancer

The TC-1 syngeneic model service for cervical cancer is an immune-competent murine platform in which HPV16 E6/E7- and c-Ha-ras-transformed TC-1 cells are engrafted into syngeneic C57BL/6 mice, providing the reference system for evaluating HPV therapeutic vaccines, checkpoint blockade, and combination immunotherapy against HPV-positive tumors. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated TC-1 / TC-1-Luc expansion and banking, standardized flank implantation, therapeutic-vaccine and checkpoint dosing schedules, E7-specific immune monitoring by tetramer staining, ELISPOT, and intracellular cytokine staining, and full endpoint pathology — all configured around each sponsor’s vaccine platform, regimen, and immunological endpoint.

Overview of TC-1 Syngeneic Model for Cervical Cancer

TC-1 was purpose-built for immunology: derived at the University of Pennsylvania by Lin and colleagues and described in 1996 in Cancer Research, the line was generated by co-transforming primary lung epithelial cells from a C57BL/6 mouse with the HPV16 E6 and E7 oncogenes together with an activated c-Ha-ras oncogene. The design logic was exact — engineer a tumor that stably expresses the E7 oncoprotein, the dominant tumor antigen of HPV-driven cervical cancer, while growing in a fully immunocompetent syngeneic host where antigen presentation, T-cell priming, and effector responses all remain intact. The line is MHC class I positive (H-2K^b, H-2D^b), presents well-defined E7 CD8⁺ T-cell epitopes, and retains E6/E7 expression through repeated passage, properties that made it the single most widely used preclinical testbed for HPV therapeutic vaccine development — from peptide and protein vaccines to DNA, dendritic-cell, and bacterial-vectored platforms.

Fig 1. SPECT/CT in the shRNA-modified TC-1 model 1 hour after injection of ^99mTc-Nbs C3 or E2. (Broos, Katrijn, et al., 2017)

In vivo, TC-1 cells grow briskly in C57BL/6 mice — flank tumors are typically palpable within about a week of implantation — yet remain immunologically tractable: antibody-mediated CD8⁺ T-cell depletion abolishes vaccine-induced control, formally demonstrating the CD8 dependence that the model was built to interrogate. Established tumors respond to therapeutic vaccination with growth inhibition or regression, and the model is where the now-canonical finding that vaccine efficacy is amplified by checkpoint blockade was established; cytokine therapies (IL-12, IL-2), adoptive cell transfer, and bispecific or innate-activating combinations have all been benchmarked on this line. The luciferase-tagged derivative TC-1-Luc, validated for whole-animal imaging, extends the platform to quantitative, longitudinal tumor tracking, while the model’s relevance extends beyond cervix to other HPV-driven malignancies. For sponsors developing E7-directed immunotherapies, TC-1 remains the mandatory, universally accepted first-line syngeneic system.

Cell Line Information: TC-1

The table below consolidates the key biological, cultural, and modeling characteristics of the TC-1 line and its luciferase-labeled derivative TC-1-Luc.

Our Services

Few models demand as much immunological craft as an E7-positive syngeneic tumor, and Alfa Cytology brings exactly that: authenticated TC-1 / TC-1-Luc banks, standardized C57BL/6 implantation, precisely scheduled vaccine-and-checkpoint regimens, and E7-specific immune analytics alongside endpoint pathology — all run as one accountable preclinical program.

Workflow of TC-1 Syngeneic Model Construction

Construction follows the established flank-engraftment methodology used across the HPV vaccine field: TC-1 cells are expanded under authenticated conditions, implanted subcutaneously into C57BL/6 mice, grown to a standardized baseline, randomized, treated per regimen, and analyzed with E7-specific immune endpoints. The workflow comprises the following stages.

1. Cell authentication and banking: TC-1 or TC-1-Luc cells are STR/identity-verified, confirmed mycoplasma-negative, and expanded into low-passage working banks under standardized RPMI-1640 culture conditions.
2. Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at the study-specified dose of approximately 2 × 10⁵ to 1 × 10⁶ cells in 100 μL of PBS or a Matrigel-supported suspension.
3. Anesthesia and implantation: C57BL/6 mice are anesthetized with isoflurane, and TC-1 cells are implanted subcutaneously into the flank using a fine-gauge needle.
4. Establishment monitoring and randomization: Tumors are monitored by palpation and caliper measurement from approximately day 5; animals are randomized into treatment arms once tumors reach approximately 5 mm, balancing baseline volumes across groups.
5. Vaccine and therapy administration: Experimental arms — therapeutic or prophylactic vaccine regimens, anti-PD-1/PD-L1/CTLA-4 checkpoint inhibitors, cytokine therapies, adoptive cell transfer, and combinations — are administered per study design with scheduled body-weight and toxicity monitoring.
6. E7-specific immune monitoring: Peripheral blood, spleen, and tumor-infiltrating lymphocytes are sampled on a study-defined schedule for E7-specific CD8⁺ T-cell quantification by tetramer staining, IFN-γ ELISPOT, and intracellular cytokine staining, alongside tumor-growth tracking.
7. Endpoint and histopathological analysis: Endpoints integrate tumor-growth curves, survival, and final tumor weight with tumor-infiltrating-lymphocyte profiling by multi-parametric flow cytometry and histopathology (H&E with CD8, Ki67, and marker-specific immunohistochemistry); mechanism studies may include immune-subset depletion arms to establish effector dependence.

Fig 2. TC-1 Syngeneic Model construction workflow.

Case Study-TC-1 Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the TC-1 platform spanning therapeutic vaccine evaluation, checkpoint combination assessment, and immune-mechanism studies in HPV-positive tumor settings. In these studies, engrafted TC-1 tumors were grown to standardized baseline volumes, treated per randomized regimens, and characterized at endpoint by tumor-burden analysis, E7-specific immune monitoring, and histopathology. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology combines HPV vaccine-field expertise with disciplined immune-analytics execution, so every TC-1 study delivers both tumor efficacy data and the E7-specific immunological evidence sponsors need for mechanism claims.

• Focused experience with E7-positive syngeneic models and therapeutic-vaccine study designs spanning prophylactic and therapeutic settings.
• A single coordinated team managing cell banking, implantation, vaccine/checkpoint logistics, tetramer and ELISPOT analytics, and pathology under one quality framework.
• Standardized randomization at approximately 5 mm tumor diameter with balanced baselines across arms.
• Endpoint panels pairing tumor efficacy with E7-specific CD8⁺ T-cell quantification and tumor-infiltrating-lymphocyte profiling.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your cervical cancer program targets HPV E6/E7 with therapeutic vaccines, checkpoint combinations, or novel immunotherapy platforms, Alfa Cytology is ready to build the study around your platform. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the TC-1 syngeneic model service.

For research use only. Not intended for any clinical use.